Iterum Therapeutics Announces Partnership for Commercialization
Iterum Therapeutics plc (Nasdaq: ITRM), focused on innovative antibiotics, recently took a significant step towards addressing multi-drug resistant infections by partnering with EVERSANA Life Science Services, LLC.
Overview of the Partnership
Through a newly formed collaboration, Iterum will leverage EVERSANA's extensive expertise in sales and commercialization. This partnership aims to accelerate the launch of ORLYNVAH™, the first oral penem antibiotic available in the United States, anticipated to hit the market by the fourth quarter of 2025.
According to Corey Fishman, Iterum’s Chief Executive Officer, this partnership is an essential move to quickly get ORLYNVAH™ into the hands of prescribers and patients. The collaboration emphasizes the vital need for effective treatment in cases of uncomplicated urinary tract infections (uUTIs), particularly where patients have limited or no options.
Conference Call Announcement
In light of this partnership, Iterum will host a conference call to discuss further details. The call is set for 4:30 p.m. Eastern Time, where stakeholders can gain insights into the future directions of the company and its initiatives related to ORLYNVAH™. Interested parties can access the conference through a dial-in method.
Understanding Urinary Tract Infections
UTIs represent a common health issue, with millions of individuals affected each year. They are particularly challenging due to rising antibiotic resistance. It is estimated that nearly 30% of uUTIs in the U.S. are caused by quinolone non-susceptible pathogens, contributing to treatment difficulties.
The Significance of ORLYNVAH™
ORLYNVAH™ symbolizes a breakthrough in the battle against resistant bacterial infections. With its ability to effectively combat pathogens, it will provide new hope for individuals suffering from uUTIs, especially women who face a higher risk of recurring infections.
About Iterum Therapeutics plc
Iterum is dedicated to combating the challenges posed by multi-drug resistant pathogens through the development of innovative anti-infective agents. Their lead compound, sulopenem, is pivotal in addressing uUTIs and is supported by strong clinical data demonstrating its efficacy against various resistant bacteria.
Commitment to Patients
In their ongoing mission, Iterum focuses on delivering impactful solutions that significantly improve the quality of life for those affected by serious infections. The partnership with EVERSANA aligns with this goal to ensure comprehensive support through marketing, logistics, and regulatory affairs, ensuring ORLYNVAH™ reaches those in need as swiftly as possible.
Looking Ahead
As Iterum prepares for the commercial launch of ORLYNVAH™ in collaboration with EVERSANA, both companies are committed to addressing the urgent healthcare needs of patients suffering from hard-to-treat infections. Together, they aspire to not only expand treatment options but also provide extensive resources and support systems aimed at healthcare professionals and patients alike.
Frequently Asked Questions
What is ORLYNVAH™?
ORLYNVAH™ is an innovative oral penem antibiotic specifically designed for treating uncomplicated urinary tract infections caused by resistant pathogens.
When is ORLYNVAH™ expected to be launched?
Iterum Therapeutics anticipates launching ORLYNVAH™ in the U.S. by the fourth quarter of 2025.
Who is EVERSANA?
EVERSANA is a leading provider of global services aimed at delivering patient-centric life sciences solutions across all stages of the product lifecycle.
What is the importance of this partnership?
This partnership is crucial for Iterum as it leverages EVERSANA's commercialization expertise to ensure swift market access for ORLYNVAH™, improving treatment options for patients.
How can I learn more about Iterum Therapeutics?
For more information about Iterum Therapeutics and their innovative products, please visit their official website.
